Carglumic acid
From Wikipedia, the free encyclopedia
 |
|
|
Carglumic acid
|
|
| Systematic (IUPAC) name | |
| N-Carbamoyl-L-glutamic Acid | |
| Identifiers | |
| CAS number | |
| ATC code | A16 |
| PubChem | ? |
| Chemical data | |
| Formula | C6H10N2NaO5 |
| Mol. mass | 190.2 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 30% |
| Protein binding | Undetermined |
| Metabolism | Partial |
| Half life | 4.3 to 9.5 hours |
| Excretion | Fecal (60%) and renal (9%, unchanged) |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. |
unknown |
| Legal status | |
| Routes | Oral |
Carglumic acid is an orphan drug, marketed by Orphan Europe under the trade name Carbaglu. Carglumic acid is used for the treatment of hyperammonaemia in patients with N-acetylglutamate synthase deficiency. The initial daily dose ranges from 100 to 250 mg/kg, adjusted thereafter to maintain normal plasma levels of ammonia.
[edit] References
- Elpeleg O, Shaag A, Ben-Shalom E, Schmid T, Bachmann C (2002). "N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy". Ann Neurol 52 (6): 845–9. PMID 12447942.
